Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates

Company Performance - Precision BioSciences reported a quarterly loss of $2.83 per share, significantly worse than the Zacks Consensus Estimate of a loss of$0.79, representing an earnings surprise of -258.23% [1] - The company posted revenues of $0.58 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 93.22$13.12 million a year ago [2] - Over the last four quarters, Precision BioSciences has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Precision BioSciences shares have declined approximately 17.7% since the beginning of the year, while the S&P 500 has gained 20.1% [3] - The current status of estimate revisions for the company is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.43 on revenues of$9.5 million, and for the current fiscal year, it is $4.08 on revenues of$85.4 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Precision BioSciences operates, is currently in the top 36% of Zacks industries, suggesting a favorable environment for stock performance [8]